In this review, we will focus on the recent progress on mesenchymal stem cells (MSCs) derived cardiomyocytes for cardiac regeneration after myocardial infarction (MI).
The objective of the current study was to analyze the association between renal function and guideline-recommended drug therapy in patients with coronary heart disease.
